Jelix Fund 1 leads an oversubscribed seed round to support Gelomics, a company revolutionizing biomedical R&D with superior 3D cell culture technologies that provide ethical and accurate alternatives to animal testing.

Information on the Target

Gelomics is an innovative company focused on advancing biomedical research and development by providing scientists with the ability to cultivate three-dimensional (3D) cell cultures. These 3D models serve as accurate representations of human biology and present ethical alternatives to traditional animal testing methods. The company aims to address the limitations of conventional two-dimensional (2D) cell cultures, which frequently yield misleading results that do not effectively translate to human physiology and disease.

Founded by a team of biomaterials experts with significant experience in the field, Gelomics has developed technology that enhances the predictability and reliability of in vitro cellular research. Their recently completed oversubscribed seed funding round, led by Jelix Fund 1 with contributions from QIC and Angelloop, will facilitate the scaling of production and sales distribution to optimize product-market fit.

Industry Overview in the Target's Specific Country

The biomedical industry has seen considerable growth globally, particularly with the ongoing shift towards more ethical and accurate methodologies for drug development. As regulatory bodies globally move to phase out animal te